000504.SZ
Landfar Bio-medicine Co., Ltd.
SZSE · Healthcare · M 科研服务 · CN
CNY 8.14
−3.44%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 512.8M | 415.9M | 134.4M | 136.8M | 200.3M |
| Cost of Revenue | 411.2M | 324.1M | 43.8M | 43.7M | 70.5M |
| Gross Profit | 101.6M | 91.8M | 90.6M | 93.1M | 129.8M |
| Operating Expenses | |||||
| R&D Expense | 7.0M | 7.7M | 9.7M | 12.6M | 10.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 37.9M | 44.3M | 52.5M | 52.4M | 53.6M |
| Selling & Marketing Expense | 18.6M | 22.1M | 30.8M | 38.4M | 60.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 71.9M | 79.1M | 94.0M | 113.7M | 136.7M |
| Cost and Expenses | 483.0M | 403.2M | 137.8M | 157.4M | 207.3M |
| Operating Income (EBIT) | 37.2M | 20.0M | (20.8M) | (45.7M) | (26.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 37.2M | 19.7M | (20.9M) | (44.7M) | (21.6M) |
| Income Tax Expense | 1.6M | 1.7M | 3.1M | 2.1M | 7.9M |
| Bottom Line | |||||
| Net Income | 42.1M | 28.8M | (19.8M) | (28.2M) | (12.5M) |
| Earnings from Cont. Ops | 32.1M | 18.1M | (23.9M) | (46.8M) | (29.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 42.1M | 28.8M | (19.8M) | (28.2M) | (12.5M) |
| Per Share | |||||
| Basic EPS | CN¥0.13 | CN¥0.09 | (CN¥0.06) | (CN¥0.09) | (CN¥0.04) |
| Diluted EPS | CN¥0.13 | CN¥0.09 | (CN¥0.06) | (CN¥0.09) | (CN¥0.04) |
| Revenue Per Share | CN¥1.55 | CN¥1.30 | CN¥0.41 | CN¥0.44 | CN¥0.64 |
| Shares | |||||
| Basic Shares Outstanding | 330.4M | 320.3M | 330.8M | 313.0M | 311.4M |
| Diluted Shares Outstanding | 330.4M | 320.3M | 330.8M | 313.0M | 311.4M |
| Profitability Metrics | |||||
| EBITDA | — | 48.6M | (6.1M) | (33.5M) | (14.1M) |
| D&A | — | 28.5M | 14.7M | 12.2M | 12.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026